Actively Recruiting

Age: 18Years +
All Genders
ID07130799

Evaluation of the Innate Immune Response Through Monocyte HLA-DR Monitoring During Severe Intra-abdominal Candidiasis in Critically Ill Patients

Led by Central Hospital, Nancy, France · Updated on 2026-02-09

100

Participants Needed

1

Research Sites

25 weeks

Total Duration

On this page

Sponsors

C

Central Hospital, Nancy, France

Lead Sponsor

H

Hospices Civils de Lyon

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying intra-abdominal candidiasis (IAC), a serious fungal infection often found in critically ill patients. This observational study aims to understand why some patients develop invasive IAC while others only have harmless colonization. It focuses on the role of innate immunity, specifically measuring monocyte HLA-DR expression, which may be reduced in patients who develop IAC compared to those with severe bacterial infections in the abdomen. The study involves monitoring patients with severe intra-abdominal infections, divided into two groups: those with IAC and those with bacterial intra-abdominal infections without fungal involvement. Researchers analyze immune markers like monocyte HLA-DR expression and CD4+ T lymphocyte counts. These assessments are done to compare immune function between the groups and better understand immune dysfunction related to fungal infection risk. Participants are patients admitted to intensive or intermediate care units for severe intra-abdominal infections requiring urgent surgery. Immune markers are measured from the day of surgery through seven days post-surgery. Researchers also track changes in immune cell populations, the impact of immune dysfunction on hospital outcomes up to 28 days, and correlate immune status with infection occurrence. The study helps improve early identification of patients at risk for invasive candidiasis and lasts from surgery through hospital stay with close immune monitoring.

CONDITIONS

Brief Title

Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patient (≥ 18 years old)
  • Patient admitted to ICU or intermediate care unit for severe intra-abdominal infection requiring urgent abdominal surgery
  • Presence of at least one risk factor for intra-abdominal candidiasis, including abdominal surgery within the last 7 days, supramesocolic gastrointestinal perforation, healthcare-associated intra-abdominal infection, community-acquired intra-abdominal infection in an immunocompromised patient, intra-abdominal infection complicated by septic shock, or broad-spectrum antibiotic exposure within 72 hours prior to surgery
  • And/or a Peritonitis Score ≥ 3 out of 4
  • Patient affiliated with or benefiting from a national health insurance system
  • Patient who has received full information about the clinical study
Not Eligible

You will not qualify if you...

  • Radiologically guided drainage without surgery
  • Infected acute pancreatitis
  • Limitation or withdrawal of life-sustaining treatments
  • Moribund patient with an expected life expectancy < 48 hours
  • Woman of childbearing potential without effective contraception
  • Refusal to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Within 7 days after abdominal surgery

Participants undergo evaluation related to severe intra-abdominal infections and immune response monitoring including blood tests for monocyte HLA-DR expression and lymphocyte counts.

Daily visits from Day 0 (surgery) to Day 7 post-surgery

Long-term Monitoring

Duration - Up to 28 days after surgery

Participants are monitored for immune dysfunction impact on in-hospital mortality and infection source control.

Visits as needed during hospital stay up to 28 days

Trial Site Locations

Total: 1 location

1

CHRU de NANCY

Vandœuvre-lès-Nancy, France, 54500

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

PROTECT-ICU: Impact of an Educational Intervention on the Im...

Post Intensive Care Syndrome (PICS)

Actively Recruiting

2 locations

Establishment of a Multi-Center Big Data System for Severe I...

Critical Illness

Actively Recruiting

1 location

A Multi-Modal Combination Intervention to Promote Cognitive ...

Critical Illness

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here